Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

603
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
603
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

2.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
2.2K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

307
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
307
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

615
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
615
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

380
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
380

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Left ventricular non-compaction in heart failure: contemporary perspective on diagnostic challenges and treatment opportunities.

Heart failure reviews·2026
Same author

Giant cell myocarditis or sarcoidosis? Time to develop clinically driven non-invasive decision algorithms in inflammatory myocardial diseases: integrating clinical features, biomarkers and multimodality imaging.

Expert review of cardiovascular therapy·2026
Same author

Highlights from the 2025 annual meeting of the ESC Working Group on Myocardial & Pericardial Diseases.

European heart journal·2026
Same author

Outpatient worsening heart failure in transthyretin amyloid cardiomyopathy: Findings from ATTRibute-CM.

European journal of heart failure·2026
Same author

Sex-Dependent Fibroblast Signatures in Heart Failure: Toward Stratified Anti-Fibro-Inflammatory Therapies.

ESC heart failure·2026
Same author

Current state of knowledge on the epidemiology, aetiology, diagnosis, and management of heart involvement in eosinophilia. A Clinical Consensus Statement of the ESC Working Group on Myocardial & Pericardial Diseases.

European journal of heart failure·2026

Related Experiment Video

Updated: Dec 29, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.5K

Coronary microvascular dysfunction in hypertrophy and heart failure.

Paolo G Camici1, Carsten Tschöpe2,3,4, Marcelo F Di Carli5,6,7

  • 1Vita Salute University and San Raffaele Hospital, Milano, Italy.

Cardiovascular Research
|January 31, 2020
PubMed
Summary

Left ventricular hypertrophy (LVH) causes coronary microvascular dysfunction (CMD) through capillary rarefaction and arteriole remodeling. This dysfunction is linked to heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).

Keywords:
Coronary vasculatureHeart failureHypertrophyLeft ventricle

More Related Videos

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice
06:39

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice

Published on: April 13, 2015

15.5K
Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
08:35

Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction

Published on: August 17, 2022

2.9K

Related Experiment Videos

Last Updated: Dec 29, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.5K
Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice
06:39

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice

Published on: April 13, 2015

15.5K
Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
08:35

Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction

Published on: August 17, 2022

2.9K

Area of Science:

  • Cardiology
  • Pathophysiology
  • Vascular Biology

Background:

  • Left ventricular (LV) hypertrophy (LVH) involves increased cardiomyocyte size, occurring physiologically or pathologically.
  • Both primary (genetic) and secondary (LV overload) LVH are associated with coronary microvascular dysfunction (CMD).
  • CMD in LVH stems from capillary rarefaction and intramural coronary arteriole remodeling, impacting the entire left ventricle.

Purpose of the Study:

  • To review experimental and clinical studies on CMD mechanisms in LVH.
  • To explore the link between CMD and heart failure with preserved (HFpEF) and reduced (HFrEF) ejection fraction in LVH patients.

Main Methods:

  • Review of existing experimental and clinical research.
  • Analysis of mechanisms underlying CMD in LVH.
  • Examination of evidence connecting CMD to HFpEF and HFrEF development and progression.

Main Results:

  • LVH, whether primary or secondary, consistently shows evidence of CMD.
  • CMD is characterized by capillary rarefaction and adverse remodeling of coronary arterioles.
  • Patients with LVH, including those with hypertrophic cardiomyopathy, are at risk for developing both HFpEF and HFrEF, with CMD playing a key role.

Conclusions:

  • Coronary microvascular dysfunction is a significant consequence of left ventricular hypertrophy.
  • CMD contributes to the development and progression of heart failure (both HFpEF and HFrEF) in patients with LVH.
  • Understanding CMD mechanisms in LVH is crucial for managing heart failure in affected individuals.